Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing BRAFV600E-Mutated Erdheim-Chester Disease: A Case Report

被引:3
|
作者
Razanamahery, Jerome [1 ]
Abdallahoui, Maroua [1 ]
Chabridon, Guillaume [2 ]
Fromont, Agnes [3 ]
Tarris, Georges [4 ]
Idbaih, Ahmed [5 ]
Comby, Pierre Olivier [6 ]
Godard, Francois [7 ]
Haroche, Julien [8 ]
Audia, Sylvain [1 ]
Bonnotte, Bernard [1 ]
机构
[1] Dijon Univ Hosp, Dept Internal Med & Clin Immunol, Dijon, France
[2] Dijon Univ Hosp, Dept Psychiat, Dijon, France
[3] Dijon Univ Hosp, Dept Neurol, Dijon, France
[4] Dijon Univ Hosp, Dept Pathol, Dijon, France
[5] Sorbonne Univ, Hop Univ Pitie Salpetriere, Paris Brain Inst ICM, Inst Cerveau,Inserm,CNRS,AP HP,DMU Neurosci, Paris, France
[6] Dijon Univ Hosp, Dept Neuroradiol, Dijon, France
[7] Ctr Georges Francois Leclerc, Nucl Med Dept, Dijon, France
[8] Hop La Pitie Salpetriere, Natl Reference Ctr Histiocytosis, Dept Internal Med 2, Paris, France
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
histiocytosis; Erdheim-Chester disease; psychosis; cerebellar syndrome; interferon; BRAF inhibitor; NEOPTERIN;
D O I
10.3389/fimmu.2022.918613
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Erdheim-Chester disease (ECD) is a rare condition with underestimated neurological involvement. Mild psychiatric symptoms such as mood swings have been rarely described in the clinical spectrum of neuro-ECD. We here describe the first patient with psychiatric manifestations of delirium revealing ECD with neurological involvement with favorable evolution under interferon followed by BRAF inhibitor monotherapy. An 81-year-old woman was referred to the hospital because of delirium and severe cognitive impairment associated with a cerebellar syndrome. Brain magnetic resonance imaging showed "FLAIR-changes" lesions in the pons and upper cerebellum peduncles. Blood and cerebrospinal fluid (CSF) analyses showed normal results except for an elevated neopterin level in the CSF. Whole-body CT scan ((18)FDG-PET) showed peri-nephric fat infiltration and aorta adventitia sheathing with radiotracer uptake in the pons, vessels, peri-nephric fat, and bone lesions, which was characteristic of ECD. The diagnosis was confirmed on perirenal tissue biopsy, which also showed a BRAF(V600E) mutation. Treatment with interferon resulted in the resolution of delirium, and treatment with BRAF inhibitor subsequently resulted in a partial remission of all active sites. This case highlights that delirium can be the first manifestation of neurodegenerative ECD. ECD should be screened in unexplained psychiatric features as interferon and targeted therapy appear to be effective in this situation.
引用
收藏
页数:6
相关论文
共 39 条
  • [1] Dramatic Efficacy of Vemurafenib on Psychiatric Symptoms Revealing Braf-V600E Erdheim-Chester Disease
    Abdallahoui, Maroua
    Razanamahery, Jerome
    Fromont, Agnes
    Haroche, Julien
    Idbaih, Ahmed
    Chabridon, Guillaume
    Audia, Sylvain
    Bonnotte, Bernard
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S1 - S1
  • [2] Low-dose vemurafenib monotherapy in BRAFV600E-mutated Erdheim-Chester disease
    Ruan, Gordon J.
    Hazim, Antonious
    Abeykoon, Jithma P.
    Scheckel, Caleb
    Vassallo, Robert
    Ryu, Jay H.
    Tobin, W. Oliver
    Koster, Matthew J.
    Bennani, N. Nora
    Rech, Karen L.
    Young, Jason R.
    Shah, Mithun V.
    Goyal, Gaurav
    Go, Ronald S.
    LEUKEMIA & LYMPHOMA, 2020, 61 (11) : 2733 - 2737
  • [3] Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAFV600E-Mutated Erdheim-Chester Disease
    Haroche, Julien
    Cohen-Aubart, Fleur
    Emile, Jean-Francois
    Maksud, Philippe
    Drier, Aurelie
    Toledano, Dan
    Barete, Stephane
    Charlotte, Frederic
    Cluzel, Philippe
    Donadieu, Jean
    Benameur, Neila
    Grenier, Philippe A.
    Besnard, Sophie
    Ory, Jean-Paul
    Lifermann, Francois
    Idbaih, Ahmed
    Granel, Brigitte
    Graffin, Bruno
    Hervier, Baptiste
    Arnaud, Laurent
    Amoura, Zahir
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (05) : 411 - U52
  • [4] Dramatic response to encorafenib in a patient with Erdheim-Chester disease harboring the BRAFV600E mutation
    Wada, Fumiya
    Hiramoto, Nobuhiro
    Yamashita, Daisuke
    Hara, Shigeo
    Furukawa, Yutaka
    Ishii, Junko
    Nagata, Kazuma
    Nannya, Yasuhito
    Ogawa, Seishi
    Ishikawa, Takayuki
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (08) : E295 - E298
  • [5] Encorafenib for Erdheim-Chester disease harboring the BRAFV600E mutation
    Wada, Fumiya
    ANNALS OF ONCOLOGY, 2021, 32 : S359 - S359
  • [6] EFFICACY OF VEMURAFENIB IN THE TREATMENT OF ERDHEIM-CHESTER DISEASE (ECD). ABOUT A CASE
    Roldan, Perez Alicia
    Azriel, Mira Sharona
    Linares, Quevedo Ana
    Hernandez, Hernandez Yolanda
    Elices, Apellaniz Margarita
    Mucientes, Rasilla Jorge
    Penalva, Moreno Maria Jose
    Vilches, Moreno Alba
    Gimenez, Mesa Eugenio
    Vazquez, Paganini Juan
    Herraez, Garcia Regina
    HAEMATOLOGICA, 2020, 105 : 328 - 329
  • [7] FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation
    Oneal, Patricia A.
    Kwitkowski, Virginia
    Luo, Lola
    Shen, Yuan Li
    Subramaniam, Sriram
    Shord, Stacy
    Goldberg, Kirsten B.
    McKee, Amy E.
    Kaminskas, Edvardas
    Farrell, Ann
    Pazdu, Richard
    ONCOLOGIST, 2018, 23 (12): : 1520 - 1524
  • [8] A cytologic diagnosis of BRAFV600E Erdheim-Chester disease on pericardial fluid
    Chasseur, P.
    Kyriakopoulou, M.
    Vokaer, B.
    Beukinga, I.
    Arroyo, R. Casado
    Cogan, E.
    Couturier, B.
    ACTA CLINICA BELGICA, 2017, 72 (05) : 369 - 371
  • [9] Significant response to dabrafenib in a patient with Erdheim-Chester disease with BRAFV600E mutation
    Verschelden, Gil
    Van Laethem, Johan
    Velkeniers, Brigitte
    Ilsen, Bart
    Noeparast, Amir
    De Greve, Jacques
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2018, 128 (06): : 386 - 388
  • [10] Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: A case report Neurology
    Tzoulis C.
    Schwarzlmüller T.
    Gjerde I.O.
    Softeland E.
    Neckelmann G.
    Biermann M.
    Haroche J.
    Straume O.
    Vintermyr O.K.
    BMC Research Notes, 8 (1)